NASDAQ:IMUXImmunic Stock Price, Forecast & News

Immunic's stock was trading at $7.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IMUX shares have increased by 58.3% and is now trading at $12.27. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Immunic.

Immunic is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Immunic.

Immunic (NASDAQ:IMUX) issued its quarterly earnings results on Friday, May, 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.96) by $0.17. View Immunic's earnings history.

4 brokers have issued 12 month target prices for Immunic's shares. Their forecasts range from $40.00 to $58.00. On average, they anticipate Immunic's stock price to reach $46.75 in the next twelve months. This suggests a possible upside of 281.0% from the stock's current price. View analysts' price targets for Immunic.

News stories about IMUX stock have been trending very negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Immunic earned a news sentiment score of -3.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Immunic.

Immunic saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 57,800 shares, a decrease of 11.5% from the June 15th total of 65,300 shares. Based on an average daily trading volume, of 285,100 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.9% of the shares of the company are sold short. View Immunic's Current Options Chain.

Some companies that are related to Immunic include Legend Biotech (AMTI), ZIOPHARM Oncology (ZIOP), Frequency Therapeutics (FREQ), Passage Bio (ORIC), Applied Therapeutics (APLT), Kadmon (KDMN), Homology Medicines (FIXX), Eagle Pharmaceuticals (EGRX), Provention Bio (PRVB), Cue Biopharma (CUE), Passage Bio (KROS), Vanda Pharmaceuticals (VNDA), Stemline Therapeutics (STML), RAPT Therapeutics (RAPT) and Aprea Therapeutics (APRE). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Inovio Pharmaceuticals (INO), Intra-Cellular Therapies (ITCI), Novavax (NVAX), Karyopharm Therapeutics (KPTI), NVIDIA (NVDA), Ovid Therapeutics (OVID), Viking Therapeutics (VKTX), AbbVie (ABBV), Aurora Cannabis (ACB) and Advanced Micro Devices (AMD).

Immunic trades on the NASDAQ under the ticker symbol "IMUX."

Shares of IMUX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IMUX stock can currently be purchased for approximately $12.27.

Immunic has a market capitalization of $183.68 million. The company earns $-34,930,000.00 in net income (profit) each year or ($4.52) on an earnings per share basis.

The official website for Immunic is www.immunic-therapeutics.com.

Immunic's mailing address is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. The company can be reached via phone at 332-255-9818 or via email at [email protected]